we discuss the changing landscape of the management of patients with metastatic hormonesensitive prostate cancer in the context of several recently-published landmark randomized trials.In addition,we discuss several unresolved issues,including the optimal sequencing of systemic treatments and the ...
Men with metastatic hormone-sensitive prostate cancer treated with darolutamide plus ADT in the phase 3 ARANOTE trial had improved radiologic progression-free survival compared with placebo. Darolutamide Plus ADT Significantly Improves Radiologic PFS in Metastatic Hormone-Sensitive ...
We see patients with all versions of metastatic hormone-sensitive prostate cancer, in that it can be de novo metastatic, meaning that from the time of diagnosis, the first time someone heard he had prostate cancer, it had spread outside of the prostate and was metastatic from the start. It...
1. Is ADT necessary for oligometastatic hormone-sensitive prostate cancer? Our literature review revealed that no prospective randomised data are available to show whether ADT is necessary or not in patients with oligometastatic hormone-sensitive prostate cancer. ADT remains the recommended treatment for ...
Clinical Trials Test Bisphosphonates in Hormone-Sensitive Prostate Cancer.Reports on clinical trials to test the potential of biphosphonates in preventing bone loss and bone-related complications in patients with hormone-sensitive metastatic disease. Reduction of the risk of cancer-related skeletal-related...
In August 2020, the Prostate Cancer Foundation convened a working group to meet and discuss biomarkers for hormone-sensitive prostate cancer, the proceedings of which are summarized here. This meeting covered the state of clinical and biological evidence for systemic therapies in the mHSPC space, ...
To analyze the correlation between circulating tumor cell (CTC) levels and clinicopathologic parameters (prostate-specific antigen level, Gleason score, and TNM stage) in patients with metastatic hormone-sensitive prostate cancer (PCa) a... TD Reijke - 《European Urology》 被引量: 86发表: 2016年...
Androgen deprivation therapy with or without chemotherapy led to similar survival in men with advanced, metastatic hormone-sensitive prostate cancer, an updated analysis of a randomized trial showed. Gwenaelle Gravis, MD Androgen deprivation therapy (ADT) with or without chemotherapy led...
Concurrently, the incidence of metastatic hormone-sensitive prostate cancer (mHSPC) at diagnosis has significantly risen as a result, in part, of recent advances in imaging. Given the increased utilization of prostate-specific membrane antigen鈥搕argeted positron emission tomography imaging and other ...
We found that the decreased mitochondrial pyruvate influx induced by MPC inhibition converted prostate cancer cells from hormone-sensitive adenocarcinoma to NE-like cells, which are enzalutamide resistant. This study enriches our knowledge of metabolic reprogramming effects on PCa development and provides a...